Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 350Stomach Neoplasms 31Neoplasm Metastasis 30Breast Neoplasms, Male 25Neoplasms 16Inflammatory Breast Neoplasms 12Brain Neoplasms 12Carcinoma, Non-Small-Cell Lung 10Esophageal Neoplasms 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Adenocarcinoma 5Sarcoma 4Lung Neoplasms 4HER2-positive Breast Cancer 4Endometrial Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Triple Negative Breast Neoplasms 3Salivary Gland Neoplasms 3Head and Neck Neoplasms 3HER2 Positive Breast Cancer 3Cardiotoxicity 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Carcinoma, Hepatocellular 3Carcinoma, Ductal, Breast 3

Interventions

Paclitaxel 16Carboplatin 14Cisplatin 12Oxaliplatin 9Hyperthermic Intraperitoneal Chemotherapy 9Cytoreduction Surgical Procedures 9Fluorouracil 7Bevacizumab 7Doxorubicin 5Leucovorin 4Gemcitabine 4catumaxomab 3Docetaxel 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3nintedanib 2liposomal doxorubicin 2epothilone B 2Surgical Procedures, Operative 2Palliative Care 2Mitomycin 2Laparoscopy 2Interviews as Topic 2Drug Therapy 2Blood Specimen Collection 2veliparib 1tremelimumab 1talimogene laherparepvec 1strattice 1sodium thiosulfate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Peritoneal Neoplasms × Trastuzumab × Clear all
NCT01384253 2016-09-30

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Orano Med LLC

Phase 1 Completed
18 enrolled
BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡